Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on August 12, 2025, declared Interim Dividend of Rs.2 /-per equity share.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma's Board, at its August 12, 2025 meeting, approved Q1FY26 unaudited results. Consolidated revenue from operations came in at Rs. 1,328.9 crore, down about 2.5% from Rs. 1,362.6 crore in Q1FY25. Net profit fell sharply to Rs. 480.3 crore from Rs. 668.5 crore, a drop of roughly 28%, dragged by US pricing pressure and higher R&D spend. EBITDA stood at Rs. 632.7 crore with 45.5% margins. The Board declared an interim dividend of Rs. 2 per share (100% on face value of Rs. 2), with record date August 19, 2025 and payment starting August 26, 2025. The Board also approved raising authorised capital to Rs. 45 crore divided into 22.5 crore equity shares, subject to shareholder approval, and cleared the 42nd AGM notice.
The sharp year-on-year decline in net profit despite stable margins and the acknowledgement of US pricing pressure may weigh on near-term sentiment, though the interim dividend signals continued shareholder returns. The authorised capital hike indicates room for future fund-raising or stock splits, pending shareholder nod.